LAMEA Exosome Diagnostic and Therapeutic Market Size, Share & Industry Trends Analysis Report By Application (Diagnostic and Therapeutic), By Product (Reagent, Instrument, and Software), By End User, By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Exosome Diagnostic and Therapeutic Market
Market Report Description
The Latin America, Middle East and Africa Exosome Diagnostic and Therapeutic Market would witness market growth of 28.8% CAGR during the forecast period (2022-2028).
Exosomes have the potential to be a drug delivery vehicle because they have natural material transportation properties, the ability to support intrinsic long-term circulation, and high biocompatibility, all of which are ideal for the delivery of a wide range of proteins, chemicals, and nucleic acids. Exosomes have shown to be effective as intercellular communication mediators in a few studies, potentially conveying functional proteins, mRNA transcripts, and miRNAs to cells all over the body. Exosomes, which are formed from certain types of cells (such as dendritic and mesenchymal stem cells), have potential therapeutic qualities and are biocompatible and effective agents against a wide range of diseases, including organ injury and diseases of the heart, kidney, liver, and lungs.
Infectious and chronic diseases afflict Africa in equal measure. While infectious diseases continue to account for at least 69 percent of deaths on the continent, chronic disease mortality rates are significantly greater in Sub-Saharan Africa than in practically every other region of the world, for both men and women. The continent is expected to see the greatest increase in death rates from cardiovascular illness, cancer, respiratory disease, and diabetes over the next ten years. Infectious and parasitic diseases continue to get priority in government spending on healthcare training and service delivery in Africa.
In fact, in adults, total age-specific mortality rates from chronic diseases are greater than in other high-income countries, typically several times higher in younger adult age groups. Perhaps even more unexpected, existing statistics imply that overall death rates from chronic diseases are greater in Sub-Saharan Africa than in practically every other region of the world, for both men and women.
The Brazil market dominated the LAMEA Exosome Diagnostic and Therapeutic Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $21.7 million by 2028. The Argentina market is poised to grow at a CAGR of 29.5% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 28.5% during (2022 - 2028).
Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Cancer Institute
- Diagnostic Center
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Aethlon Medical, Inc.
- Capricor Therapeutics, Inc.
- Malvern Panalytical Ltd.
- NanoSomix, Inc.
- System Biosciences, LLC
- NX Pharmagen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free